Mi­rati sees more re­spons­es for KRAS drug in Keytru­da com­bo as it an­gles for an edge over Am­gen

With a fil­ing for its KRAS in­hibitor ada­gra­sib right around the cor­ner, Mi­rati is build­ing a grow­ing case against Am­gen as in­vestors watch with bat­ed breath. Promis­ing da­ta from a tiny sub­group of lung can­cer pa­tients treat­ed with an ada­gra­sib com­bo could whet in­vestors’ ap­petites just enough, but how will Am­gen re­spond?

In a short up­date in its Q3 earns, Mi­rati said a com­bi­na­tion of ada­gra­sib and Mer­ck’s Keytru­da post­ed four par­tial re­spons­es among eight pre­vi­ous­ly un­treat­ed, ad­vanced non-small cell lung can­cer pa­tients in a Phase Ib test, cast­ing new hope the biotech could seize a leg up on Am­gen in the fledg­ing KRAS in­hibitor race.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER